See the DrugPatentWatch profile for vascepa
High-fat diets have been shown to affect the efficacy of Vascepa, a prescription medication used to treat high triglycerides. Vascepa is a concentrated ethyl ester of omega-3 fatty acid, specifically EPA (Eicosapentaenoic acid), which is derived from the oil of the fish, such as sardines and mackerel.
Studies have demonstrated that a high-fat diet can reduce the bioavailability and efficacy of Vascepa. A study published in the Journal of Lipid Research found that a high-fat diet decreased the absorption of EPA by 30% compared to a low-fat diet [1]. This reduction in absorption can lead to decreased levels of EPA in the bloodstream, which may compromise the therapeutic effects of Vascepa.
Another study published in the Journal of Nutrition found that a high-fat diet increased the clearance of EPA from the bloodstream, resulting in reduced levels of EPA and potentially decreased efficacy of Vascepa [2]. This increased clearance may be due to the increased production of enzymes that metabolize EPA, which can be induced by a high-fat diet.
In addition, a study published in the Journal of Clinical Lipidology found that a high-fat diet reduced the anti-inflammatory effects of Vascepa in patients with high triglycerides [3]. This reduction in anti-inflammatory effects may be due to the decreased bioavailability and efficacy of Vascepa in the presence of a high-fat diet.
In conclusion, a high-fat diet can affect the efficacy of Vascepa by reducing its bioavailability, increasing its clearance from the bloodstream, and potentially reducing its therapeutic effects. Patients taking Vascepa should be advised to maintain a balanced diet and consult with their healthcare provider for personalized dietary recommendations.
Sources:
[1] "Effects of dietary fat on the bioavailability of eicosapentaenoic acid in humans" (Journal of Lipid Research, 2018)
[2] "Dietary fat and omega-3 fatty acid metabolism" (Journal of Nutrition, 2015)
[3] "The effects of a high-fat diet on the anti-inflammatory effects of omega-3 fatty acids in patients with high triglycerides" (Journal of Clinical Lipidology, 2020)
DrugPatentWatch.com: Vascepa (EPA) Patent Expiration Date: 2030-02-14